Korean J Intern Med.
2021 May;36(3):491-514. 10.3904/kjim.2020.213.
2020 Korean guidelines for the management of metastatic prostate cancer
- Kim IH1
- Shin SJ2
- Kang BW3
- Kang J4
- Kim D5
- Kim M6
- Kim JY7
- Kim CK8
- Kim HJ9
- Maeng CH10
- Park K11
- Park I12
- Bae WK13
- Sohn BS14
- Lee MY15
- Lee JL16
- Lee J17
- Lim ST18
- Lim JH19
- Chang H20
- Jung JY21
- Choi YJ22
- Kim YS23
- Cho J24
- Joung JY25
- Park SH26
- Lee HJ
27
- Affiliations
-
- 1Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 3Department of Oncology/ Hematology, Kyungpook National University Hospital, Daegu, Korea
- 4Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- 5Division of Hematology & Medical Oncology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea
- 6Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- 7Division of Hemato-Oncology, Keimyung University Dongsan Hospital, Daegu, Korea
- 8Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- 9Division of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- 10Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea
- 11Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea
- 12Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
- 13Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea
- 14Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea
- 15Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
- 16Department of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 17Division of Medical Oncology, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea
- 18Department of Oncology, Yonsei University Wonju College of Medicine, Wonju, Korea
- 19Department of Hematology/Oncology, Inha University School of Medicine, Incheon, Korea
- 20Division of Medical Oncology, International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea
- 21Division of Hemato-Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
- 22Division of Hematology-Oncology, Department of Medicine, Korea University Anam Hospital, Seoul, Korea
- 23Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 24Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
- 25Center for Urologic Cancer, National Cancer Center, Goyang, Korea
- 26Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 27Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
- KMID: 2515681
- DOI: http://doi.org/10.3904/kjim.2020.213
Abstract
- In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations
- The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Next-Generation Sequencing in Prostate Cancer
- Expression of Survivin Correlated with Antiapoptosis in Benign Prostate Hyperplasia and Prostate Cancer
